For most Australians, the medicine business begins with a visit to the doctor and ends with a prescription collected from the local pharmacy. Behind that simple transaction lies one of Australia's largest and most carefully regulated industries, involving pharmaceutical manufacturers, importers, wholesalers, pharmacies, medical professionals, government agencies and logistics companies.

It is a business that combines commercial innovation with public policy. Companies invest billions of dollars developing new medicines, while governments seek to ensure those medicines remain affordable for patients.

A Multi-Billion Dollar Industry

Australia's pharmaceutical sector consists of several interconnected businesses.

Research companies develop new medicines, often after years of laboratory work and clinical trials. Manufacturers produce medicines domestically or overseas. Importers and wholesalers distribute products throughout Australia before they arrive at community pharmacies, hospital pharmacies and healthcare providers.

Each participant earns revenue, but each also operates within a highly regulated environment designed to protect patient safety and ensure medicines are available when needed.

The PBS Changes the Market

Unlike many countries, Australia does not leave prescription medicine pricing entirely to market forces.

The Pharmaceutical Benefits Scheme (PBS), established in 1948, subsidises thousands of medicines so Australians pay only a capped contribution rather than the full commercial price. The Australian Government pays the remaining cost directly to pharmacies on behalf of eligible patients.

This creates a distinctive commercial model.

Pharmaceutical companies negotiate with government for PBS listing. Once listed, a medicine becomes accessible to millions of Australians, although companies generally accept lower prices than they may receive in less regulated markets.

Who Decides Which Medicines Are Covered?

Not every approved medicine automatically appears on the PBS.

Medicines must first be approved for safety, quality and effectiveness before an independent expert committee, the Pharmaceutical Benefits Advisory Committee (PBAC), assesses whether they provide sufficient clinical benefit and value for taxpayers. The Federal Government then decides whether to list the medicine following that assessment and commercial negotiations.

The process aims to balance innovation with affordability.

Pharmacies: More Than Retail Stores

Community pharmacies are often viewed simply as retailers, but they operate under a unique business model.

Their income comes from several sources:

• Dispensing PBS prescriptions.
• Selling non-prescription medicines.
• Health services such as vaccinations and medication reviews.
• Front-of-store retail products including vitamins, cosmetics and personal care items.

The dispensing of PBS medicines is supported through government funding arrangements that include professional fees and wholesale payments, recognising that pharmacies provide healthcare services as well as retail operations.

Delivering Medicines Across Australia

Getting medicines to consumers is a sophisticated logistics exercise.

Large pharmaceutical wholesalers supply thousands of pharmacies each day, often delivering multiple times daily in metropolitan areas while maintaining cold-chain requirements for temperature-sensitive medicines.

Remote Australia presents additional challenges.

Medicines may travel by road, air and sea before reaching rural pharmacies, Aboriginal health services and isolated communities. Despite Australia's vast geography, the objective is continuity of supply regardless of where patients live.

Home delivery has also become increasingly important, particularly for elderly Australians, people with disabilities and those managing chronic illnesses.

Why Continuity Matters

For many Australians, medicines are not occasional purchases.

People managing diabetes, heart disease, asthma, arthritis or high blood pressure may rely on uninterrupted treatment for decades.

The PBS helps provide continuity by reducing the financial burden of long-term medication. Australia's National Medicines Policy also emphasises timely and affordable access to essential medicines. In 2022–23, more than 335 million prescriptions were dispensed to 17.8 million Australians, illustrating the scale of this system.

Commercial Success and Public Health

Australia's medicine industry illustrates an unusual partnership between private enterprise and government.

Pharmaceutical companies seek returns on research investment. Pharmacies operate as private businesses. Wholesalers maintain complex national distribution networks.

At the same time, governments subsidise medicines because healthier Australians generally experience better quality of life and may require fewer hospital admissions and other costly health interventions.

That combination has helped make Australia's pharmaceutical system one of the country's most significant healthcare investments.

The Times View

The medicine business in Australia extends far beyond manufacturing tablets and filling prescriptions. It is an integrated ecosystem linking scientific research, commercial enterprise, government funding and sophisticated logistics. The Pharmaceutical Benefits Scheme sits at the centre of that system, helping millions of Australians access medicines that might otherwise be unaffordable while supporting a nationwide network that delivers treatments from the laboratory bench to the patient's hand.